GLP Watchdog has unveiled a comprehensive online register to improve transparency in the rapidly expanding market for GLP-1 weight-loss medicines, amidst increasing regulatory scrutiny and warnings issued to sellers across the US.
GLP Watchdog has opened a public register aimed at bringing more clarity to the fast-growing online market for GLP-1 weight-loss medicines in the US, where consumers may struggle to see who is selling the drug, which pharmacy is filling the prescription and what the real monthly cost will be. The site says it rates more than 500 sellers and includes a searchable archive of more than 180 FDA warning letters, reflecting a category that has expanded quickly through telehealth firms, compounding pharmacies and med spas. GLP Watchdog says the aim is to place those details in one consistent format for shoppers comparing providers.
The launch comes as scrutiny of the sector intensifies. In research published on its own site, GLP Watchdog said it analysed 186 FDA warning letters issued between 2023 and 2026 and found a sharp rise in enforcement, with 109 letters in 2025 and 65 in 2026. The most common issue, it said, was the unlawful sale of unapproved or misbranded drugs to consumers, accounting for 87 of the letters.
The register gives each seller a score out of 10 based on six measures: value, effectiveness, user experience, trust and safety, accessibility and support. According to the site, the ratings are built only from published information, including the cheapest monthly price a seller advertises, pharmacy accreditation, prescriber oversight and FDA enforcement history. The company says it also includes companies that sell compounded GLP-1 products, which some other rankings omit.
GLP Watchdog says its pricing data is recorded by calendar month rather than by the promotional billing periods often used on marketing pages. It also says the archive is organised by operating company rather than by brand name, so users can more easily connect a warning letter with the business behind a seller. Entries do not treat a warning letter as an automatic disqualification, but the site says the letter is disclosed as part of each company profile. The project presents itself as an independent publisher rather than a regulator or medical body.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
